186 results
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
13 May 24
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:15am
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
1 May 24
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
8:00am
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected
8-K
EX-99.1
fbr2a11bnix
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
8-K
EX-99.1
9gjnd1zj oy3l0a5bg
19 Mar 24
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
8:30am
8-K
EX-99.1
12yy1j6o
4 Jan 24
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
4:01pm
8-K
EX-99.1
625xq8tgj7q2bx3
6 Dec 23
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
8:00am
8-K
EX-99.2
gl9e0chf4dbpl7pik4rf
29 Nov 23
Regulation FD Disclosure
8:00am
8-K
EX-99.1
wvr hcz6nk7
13 Nov 23
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:15am
8-K
EX-99.1
rwju o16bwym0p6axvs
31 Oct 23
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
8:00am
8-K
EX-99.1
4cag2wb1jgkq7i
16 Aug 23
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
4:05pm
424B5
qryvshizxe
15 Jun 23
Prospectus supplement for primary offering
4:54pm
8-K
EX-99.1
3vs5oey7h50m033mnhws
15 May 23
Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:00am